复宏汉霖(2696.HK)逆势收涨2.34% 绩后获高盛上调盈测及目标价

中金财经

Yesterday

　　中东冲突再升级，全球市场狂泻遭遇“黑色星期一”。港股三大指数今日大幅下挫，恒指盘中一度跌逾4%创逾8个月新低，最终收跌3.54%重挫近900点。科技股、金融股等多数板块基本全军覆没，医药板块未能幸免，恒生生物科技指数收跌4.1%创去年7月以来新低。板块中仅少数股票逆势上涨，其中，复宏汉霖(2696.HK)逆势收涨2.34%，报65.65港元，市值356.8亿港元。　　消息面上，复宏汉霖上周五(3月20日)发布2025年年度业绩。期内实现营收66.666亿元，同比增长16.5%；净利润8.270亿元，公司全年研发投入达24.919亿元，同比增长35.4%，在持续加大创新投入的背景下，研发投入前利润达23.425亿元，同比增长26.2%。这是公司自2023年首次实现全年盈利以来，连续三年实现营收、利润双增长，展现出稳健的盈利韧性和高质量增长能力。　　高盛最新发研报指，复宏汉霖去年下半年总收入按年升29%至38亿元，其中中国内地销售胜于预期，按年升31%至32亿元。尽管因拓展临床试验项目，令研发费用大幅上涨，但下半年盈利仍超预期，受惠于收入增长强劲和毛利率不断提升。该行将复宏汉霖今年及明年销售预测分别上调8.6%及8.3%，维持2028年销售预测不变，各年纯利预测则分别上调3,800万元、2.24亿元及1.43亿元，将其目标价由102.72港元上调至104.79港元，评级“买入”。(格隆汇) 　　

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621834777"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621834777\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621834777?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-23 18:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621834777","market":"fut","top_or_hot":-1,"title":"复宏汉霖(2696.HK)逆势收涨2.34% 绩后获高盛上调盈测及目标价","media":"中金财经","content":"<html><body><p>　　中东冲突再升级，全球市场狂泻遭遇“黑色星期一”。港股三大指数今日大幅下挫，恒指盘中一度跌逾4%创逾8个月新低，最终收跌3.54%重挫近900点。科技股、金融股等多数板块基本全军覆没，医药板块未能幸免，恒生生物科技指数收跌4.1%创去年7月以来新低。板块中仅少数股票逆势上涨，其中，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(2696.HK)逆势收涨2.34%，报65.65港元，市值356.8亿港元。\r\n\r\n　　消息面上，复宏汉霖上周五(3月20日)发布2025年年度业绩。期内实现营收66.666亿元，同比增长16.5%；净利润8.270亿元，公司全年研发投入达24.919亿元，同比增长35.4%，在持续加大创新投入的背景下，研发投入前利润达23.425亿元，同比增长26.2%。这是公司自2023年首次实现全年盈利以来，连续三年实现营收、利润双增长，展现出稳健的盈利韧性和高质量增长能力。\r\n\r\n　　<a href=\"https://laohu8.com/S/GS\">高盛</a>最新发研报指，复宏汉霖去年下半年总收入按年升29%至38亿元，其中中国内地销售胜于预期，按年升31%至32亿元。尽管因拓展临床试验项目，令研发费用大幅上涨，但下半年盈利仍超预期，受惠于收入增长强劲和毛利率不断提升。该行将复宏汉霖今年及明年销售预测分别上调8.6%及8.3%，维持2028年销售预测不变，各年纯利预测则分别上调3,800万元、2.24亿元及1.43亿元，将其目标价由102.72港元上调至104.79港元，评级“买入”。(格隆汇)\r\n\r\n　　 </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(2696.HK)逆势收涨2.34% 绩后获高盛上调盈测及目标价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(2696.HK)逆势收涨2.34% 绩后获高盛上调盈测及目标价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 18:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushizhibo/20260323/32090766.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中东冲突再升级，全球市场狂泻遭遇“黑色星期一”。港股三大指数今日大幅下挫，恒指盘中一度跌逾4%创逾8个月新低，最终收跌3.54%重挫近900点。科技股、金融股等多数板块基本全军覆没，医药板块未能幸免，恒生生物科技指数收跌4.1%创去年7月以来新低。板块中仅少数股票逆势上涨，其中，复宏汉霖(2696.HK)逆势收涨2.34%，报65.65港元，市值356.8亿港元。\r\n\r\n　　消息面上，复宏汉霖...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20260323/32090766.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260323/32090766.shtml","article_id":"2621834777","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621834777","pubTimestamp":1774262221,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"板块中仅少数股票逆势上涨，其中，复宏汉霖逆势收涨2.34%，报65.65港元，市值356.8亿港元。　　消息面上，复宏汉霖上周五发布2025年年度业绩。　　高盛最新发研报指，复宏汉霖去年下半年总收入按年升29%至38亿元，其中中国内地销售胜于预期，按年升31%至32亿元。该行将复宏汉霖今年及明年销售预测分别上调8.6%及8.3%，维持2028年销售预测不变，各年纯利预测则分别上调3,800万元、2.24亿元及1.43亿元，将其目标价由102.72港元上调至104.79港元，评级“买入”。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"Henlius (2696.HK) bucked the trend and closed up 2.34%. Goldman Sachs raised its earnings forecast and target price after the results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"中东冲突再升级，全球市场狂泻遭遇“黑色星期一”。港股三大指数今日大幅下挫，恒指盘中一度跌逾4%创逾8个月新低，最终收跌3.54%重挫近900点。科技股、金融股等多数板块基本全军覆没，医药板块未能幸免，恒生生物科技指数收跌4.1%创去年7月以来新低。板块中仅少数股票逆势上涨，其中，复宏汉霖(2696.HK)逆势收涨2.34%，报65.65港元，市值356.8亿港元。\r\n\r\n　　消息面上，复宏汉霖上周五(3月20日)发布2025年年度业绩。期内实现营收66.666亿元，同比增长16.5%；净利润8.270亿元，公司全年研发投入达24.919亿元，同比增长35.4%，在持续加大创新投入的背景下，研发投入前利润达23.425亿元，同比增长26.2%。这是公司自2023年首次实现全年盈利以来，连续三年实现营收、利润双增长，展现出稳健的盈利韧性和高质量增长能力。\r\n\r\n　　高盛最新发研报指，复宏汉霖去年下半年总收入按年升29%至38亿元，其中中国内地销售胜于预期，按年升31%至32亿元。尽管因拓展临床试验项目，令研发费用大幅上涨，但下半年盈利仍超预期，受惠于收入增长强劲和毛利率不断提升。该行将复宏汉霖今年及明年销售预测分别上调8.6%及8.3%，维持2028年销售预测不变，各年纯利预测则分别上调3,800万元、2.24亿元及1.43亿元，将其目标价由102.72港元上调至104.79港元，评级“买入”。(格隆汇)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}